Artivion (NYSE:AORT) Price Target Raised to $30.00

Artivion (NYSE:AORT) had its price target hoisted by research analysts at Lake Street Capital from $28.00 to $30.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital’s price target suggests a potential upside of 16.05% from the company’s previous close.

Several other equities research analysts have also recently weighed in on AORT. Stifel Nicolaus increased their price objective on shares of Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Needham & Company LLC lifted their price objective on Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th.

Artivion Stock Up 0.8 %

Shares of NYSE:AORT opened at $25.85 on Tuesday. The business has a fifty day simple moving average of $23.22 and a 200 day simple moving average of $20.49. Artivion has a 12-month low of $12.16 and a 12-month high of $26.26. The firm has a market cap of $1.08 billion, a P/E ratio of -107.71 and a beta of 1.75. The company has a quick ratio of 4.26, a current ratio of 6.04 and a debt-to-equity ratio of 1.07.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04. The company had revenue of $97.43 million during the quarter, compared to the consensus estimate of $92.30 million. Artivion had a positive return on equity of 3.64% and a negative net margin of 2.61%. Analysts predict that Artivion will post 0.24 earnings per share for the current year.

Institutional Trading of Artivion

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Artivion by 1.3% in the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after buying an additional 33,982 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Artivion by 5.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,686,502 shares of the company’s stock valued at $30,156,000 after purchasing an additional 80,214 shares in the last quarter. Wasatch Advisors LP grew its holdings in Artivion by 108.8% during the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock worth $22,928,000 after buying an additional 564,549 shares in the last quarter. First Eagle Investment Management LLC lifted its stake in Artivion by 8.1% during the 1st quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock valued at $12,066,000 after acquiring an additional 42,705 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Artivion by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 326,085 shares of the company’s stock worth $5,830,000 after acquiring an additional 8,090 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.